Figure 7
The retardance of apoptosis with overexpression of Bcl-xL. (A) HepG2 cells were treated by 20 μM TK VI and the expression of Bcl-xL was assessed by Immunoblot assay. (B) HepG2 cells were transfected with a pcDNA3.1 vector containing the coding sequence for Bcl-xL (Bcl-xL) or with a neomycin-resistant expression vector pcDNA3.1 (Neo, control) by Lipofectin reagent according to the manufacturer's instructions. Over-expression of Bcl-xL expression was assessed by Western blot. (C) and (D) Apoptotic cells and Dissipation of ΔΨm were quantified by FACS analysis. Results were expressed as means ± SD of triplicate experiments (each performed in duplicate). (E) HepG2 cells were treated by 20 μM TK VI for indicated times. The release of Cyto-c and Smac/DIABLO was assessed in Bcl-xL-overexpression and neo cells by Immunoblot assay. (F) Cells were treated as (C) and then autophagy was analyzed using flow cytometry with acridine orange dyeing. Asterisks indicated values significantly different from Bcl-xL-overexpression cells. **P < 0.01.